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Abstract  1 
 2 
Studying the complex mechanisms underlying breast cancer metastasis and therapy 3 
response necessitates relevant in vivo models, particularly syngeneic models with an 4 
intact immune system. Two syngeneic spontaneously metastatic sublines, D2A1-m1 5 
and D2A1-m2, were generated from the poorly metastasising BALB/c-derived D2A1 6 
cell line by serial in vivo passaging. In vivo and in vitro analyses revealed distinct and 7 
shared characteristics of the metastatic D2A1-m1 and D2A1-m2 sublines. In 8 
particular, D2A1-m1 cells are more aggressive in experimental metastasis assays, 9 
while D2A1-m2 cells are more efficient at disseminating from the primary tumour in 10 
spontaneous metastasis assays. Surprisingly, classical metastasis-associated in vitro 11 
phenotypes such as enhanced proliferation, migration and invasion are reduced in 12 
the sublines compared to the parental cell line. Further, evasion of immune control 13 
cannot fully explain their enhanced metastatic properties. By contrast, both sublines 14 
show increased resistance to apoptosis when cultured in non-adherent conditions 15 
and, for the D2A1-m2 subline, increased 3D tumour spheroid growth. Moreover, the 16 
enhanced spontaneous metastatic phenotype of the D2A1-m2 subline is associated 17 
with an increased ability to recruit an activated tumour stroma. The metastatic D2A1-18 
m1 and D2A1-m2 cell lines provide additional syngeneic models for investigating the 19 
different steps of the metastatic cascade and thereby represent valuable tools for 20 
breast cancer researchers. Finally, this study highlights that morphology and cell 21 
behaviour in 2D cell-based assays cannot be used as a reliable predictor of 22 
metastatic behaviour in vivo. 23 
 24 
 25 
Introduction 26 
To study the complex mechanisms of breast cancer metastasis and therapy 27 
response in advanced disease, it is important to have relevant in vivo models. Ideally, 28 
the model recapitulates the full metastatic cascade including growth of a primary 29 
tumour, dissemination of tumour cells into the circulation, colonisation of secondary 30 
sites and the development of macrometastatic disease. In addition, to assess the 31 
impact of the immune system, an immunocompetent syngeneic model is required. A 32 
recent study has molecularly characterised 12 mouse mammary cancer cell lines and 33 
performed phenotypic analysis of the primary tumours grown in syngeneic hosts 34 
(Yang et al., 2017). To date, the best characterised spontaneous breast cancer 35 
metastasis model is the BALB/c-derived 4T1 cell line (Aslakson and Miller, 1992) and 36 
the 4T1 sublines selected for increased metastasis to the bone and lung (Lelekakis et 37 
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al., 1999; Tester et al., 2000) or brain (Lockman et al., 2010). More recently 1 
Johnstone and colleagues have derived and characterised a spontaneously 2 
metastasising variant of the C57BL/6-derived murine medullary mammary 3 
adenocarcinoma cell line E0771 (Johnstone et al., 2015), allowing for metastasis 4 
studies to be performed in an alternative mouse strain. However, there is still an 5 
increasing demand for independent models both for study validation and to address 6 
the inter- and intra-tumour heterogeneity of human disease.  7 
 In this study we describe the generation of two breast cancer cell sublines, 8 
D2A1-m1 and D2A1-m2, derived from parental D2A1 cells. The parental D2A1 cell 9 
line was derived from a mouse mammary tumour in a BALB/c mouse implanted with 10 
the transplantable D2 hyperplastic alveolar nodule cell line (Mahoney et al., 1985; 11 
Miller et al., 1989; Morris et al., 1993). In a recent comprehensive analysis of 12 12 
mouse mammary cancer cell lines (Yang et al., 2017), D2A1 cells are classified as 13 
oestrogen receptor (ER) and ErbB2/HER2-negative, Pik3ca and Trp53 wildtype, 14 
having a 'claudin-low' transcriptional profile and assignment to the luminal B subtype. 15 
In vivo, D2A1 tumours have a spindle-cell histology with ~18% Ki67-positive cells 16 
and ~20% caspase 3-positive nuclei. It was originally reported that 4 weeks after 17 
orthotopic inoculation into immunocompromised nude BALB/c mice, 2 out of the 5 18 
mice showed visible macrometastatic disease in the lungs with the remaining mice 19 
showing lung micrometastatic disease upon histological examination (Morris et al., 20 
1993). Subsequently it was reported that parental D2A1 cells can colonise the lungs 21 
of immunocompetent BALB/c mice if injected via the tail vein in an experimental 22 
metastasis assays (Shibue and Weinberg, 2009) and that rates of spontaneous 23 
metastasis in BALB/c can be increased by pre-irradiation of the mammary gland 24 
(Bouchard et al., 2013), albeit still with a relatively low metastatic burden.  25 
 The D2A1-m1 and D2A1-m2 sublines were derived by serial inoculation of 26 
tumour cells in BALB/c mice followed by recovery from the lung tissue ex vivo. 27 
Characterisation of these two metastatic sublines demonstrates them to have both 28 
overlapping and distinct phenotypes in in vivo assays, in vitro assays and by gene 29 
expression profiling. In particular, the D2A1-m1 subline displays an enhanced ability 30 
to colonise the lungs and other tissues in experimental metastasis assays whereas 31 
the D2A1-m2 subline shows a robust and reproducible ability to colonise the lungs in 32 
a spontaneously metastasis assay (inoculation into the mammary fat pad), 33 
associated with an increased ability to recruit an activated tumour stroma. 34 
Consequently, these two D2A1 sublines provide useful and complementary models 35 
to interrogate the different stages of the metastatic cascade.  36 
 37 
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 1 
Results 2 
Generation of spontaneously metastatic D2A1 sublines 3 
The scheme for the generation of the D2A1 sublines is shown in Fig. 1A. The two 4 
sublines were derived independently. In brief, for each subline, parental D2A1 cells 5 
were inoculated orthotopically into the 4th mammary fat pad of an immunocompetent 6 
BALB/c mouse. When the primary tumour reached 10 - 12 mm in diameter, the lungs 7 
were harvested individually from each mouse at necropsy, dissociated, and placed 8 
into culture. Tumour cells that grew out were expanded and inoculated into the tail 9 
vein of a recipient mouse and 11 - 13 days later, lungs removed at necropsy. In total, 10 
three rounds of intravenous inoculation were performed resulting in the selection of 11 
the independent metastatic sublines, D2A1-m1 and D2A1-m2. 12 
 In an initial experiment to assess the metastatic competency of the selected 13 
sublines, parental D2A1, D2A1-m1 and D2A1-m2 cells were inoculated orthotopically 14 
into the mammary fat pad of recipient BALB/c mice. Animals were culled individually 15 
between days 31 and 39 when the primary tumours reached 12 - 14 mm in diameter 16 
(Fig. 1B). Consistent with the published literature (Bouchard et al., 2013; Morris et al., 17 
1993; Yang et al., 2017) parental D2A1 cells readily formed primary tumours but, with 18 
the exception of a single large metastatic nodule in one mouse, gave rise to only 19 
small metastatic nodules in the lungs and with the majority of mice having 20 
undetectable metastatic disease. All mice inoculated with D2A1-m1 and D2A1-m2 21 
cells had metastatic disease as monitored both by tumour area and number of 22 
metastatic nodules, with the D2A1-m2 subline giving rise to the highest metastatic 23 
burden in this spontaneous metastasis assay. Though there is a difference in the 24 
number of metastatic nodules in mice inoculated with the D2A1-m1 and D2A1-m2 25 
sublines and an increase in the % tumour area in the lungs, the average size of the 26 
lung nodules is similar. Of note, although the D2A1-m1 and D2A1-m2 primary 27 
tumours grew slightly faster than the parental D2A1 tumours, in subsequent 28 
experiments no differences in primary tumour growth was observed (see below).  29 
 To better mimic the clinical setting in breast cancer, spontaneous metastasis 30 
assays in BALB/c mice were then performed in which the primary tumour was 31 
surgically resected at a small size (~ 6 mm in diameter; day 11 - 13) and all mice 32 
were culled on day 43 (Fig. 1C). Despite the increased length of time of the 33 
experiment, when lungs were examined at autopsy, there was only limited metastatic 34 
disease in the parental D2A1 inoculated mice whereas the D2A1-m2 subline gave 35 
rise to extensive tumour burden in the lungs. The D2A1-m1 subline gave mixed 36 
results with 2 out of 5 mice showing no metastatic disease and the remaining 3 mice 37 
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having readily detectable macrometastatic nodules. The enhanced metastatic burden 1 
observed in mice where the primary tumour is resected (Fig. 1C) likely reflects two 2 
factors. First, in experiments where the primary tumour was not removed, mice were 3 
culled when the primary tumour reached its maximum allowable size (31 - 39 days 4 
(Fig. 1B). By contrast, following tumour resection the study was conducted over a 5 
longer time period (43 days) allowing increased growth of metastatic deposits 6 
(Francia et al., 2011). Second, in experimental mouse models, there have been 7 
numerous reports that removal of a primary tumour can enhance growth of 8 
metastatic lesions (O'Reilly et al., 1994). In addition, these observations suggest that 9 
dissemination of cells from the primary tumour is an early event.  10 
 To assess whether the immune system plays a role in limiting D2A1 tumour 11 
growth and metastasis, parental D2A1 cells and the metastatic D2A1-m2 subline 12 
were inoculated orthotopically into immunocompetent BALB/c (Supplementary Figure 13 
S1) or immunocompromised NOD scid gamma (NSG) (Fig. 2) mice. In both mouse 14 
strains, there was no significant difference in primary tumour growth but, again, the 15 
D2A1-m2 cells gave rise to a significantly increased metastatic burden in the lung. 16 
Moreover, although the primary tumours did not grow at a noticeably faster rate in the 17 
NSG compared to the BALB/c mice (Fig. 2A, Supplementary Figure S1A), it is 18 
important to note that the NSG mice experiment had to be terminated at an earlier 19 
time (and when the primary tumours were of a much smaller size) due to the 20 
extensive burden of metastatic disease in the D2A1-m2 inoculated mice (Fig. 2B). In 21 
addition, although the D2A1 parental cells showed a much reduced metastatic 22 
burden compared to the D2A1-m2 subline, the amount of D2A1 metastatic burden in 23 
the lung was greater in the immunocompromised NSG mice compared to the BALB/c 24 
mice. Although, differences in tumour growth can vary between different mouse 25 
strains (Hunter, 2006) these data suggest that both the D2A1 parental cells and their 26 
metastatic derivatives are under immune control, particularly in the metastatic setting, 27 
and that evasion of immune control cannot fully explain the enhanced metastatic 28 
properties of the metastatic subline.  29 
 30 
Experimental metastasis assays 31 
Next we assessed the ability of the two metastatic sublines to colonise secondary 32 
sites in different experimental metastasis assays. First, untagged (Fig. 3A) or 33 
luciferase tagged (Supplementary Figure S2) tumour cells were inoculated 34 
intravenously into recipient BALB/c mice. Consistent with the spontaneous 35 
metastasis assays, injection of both sublines resulted in a greater lung tumour 36 
burden than the parental cells. Interestingly, although the D2A1-m2 subline gave rise 37 
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to a higher burden of spontaneous lung metastases compared to the D2A1-m1 1 
subline (Fig. 1B), in this experimental metastasis assay it was the D2A1-m1 subline 2 
that gave rise to the greatest lung tumour burden (Fig. 3A).  3 
 Intravenous inoculation results in the majority of tumour cells lodging in the 4 
lungs. To investigate other sites of metastasis, we next performed intracardiac 5 
inoculation of tumour cells (Fig. 3B), which favours dissemination via the arterial 6 
system to the bones, brain and other organs (Bos et al., 2009; Khanna and Hunter, 7 
2005). Ex vivo IVIS imaging revealed that, again, the D2A1-m1 subline gave rise to 8 
the greatest tumour burden in the bones. Neither the D2A1 parental cells nor the 9 
metastatic sublines showed evidence of brain colonisation. 10 
 Finally, we performed intrasplenic inoculations to assess colonisation of the 11 
liver (Khanna and Hunter, 2005) (Fig. 3C). 50% of mice inoculated with parental 12 
D2A1 cells had undetectable tumour burden in the liver but both the D2A1-m1 and 13 
D2A1-m2 sublines gave rise to extensive disease with only one mouse in each group 14 
remaining tumour free.  15 
 Together these in vivo experiments, indicate that the two D2A1 sublines have 16 
different properties with the D2A1-m1 subline having a superior ability to grow in the 17 
lungs and the bones but, compared to the D2A1-m2 subline, a reduced ability to 18 
disseminate from the primary tumour. Consequently, we next addressed whether 19 
these two sublines displayed altered properties using a panel of in vitro proliferation, 20 
migration and invasion assays. 21 
 22 
D2A1 metastatic sublines in adherent culture.  23 
When growing as adherent cultures on tissue culture plastic the D2A1 metastatic 24 
sublines have distinct morphologies, with D2A1-m1 cells having a more elongated 25 
shape and D2A1-m2 cells being more rounded, compared to the parental cells (Fig. 26 
4A; Supplementary Fig. S3). These different morphologies did not impact on the 27 
plating efficiency as exemplified by all three cell lines giving rise to the same number 28 
of colonies in a colony formation assay (Fig. 4B). By contrast, in this assay, it was 29 
notable that the two metastatic sublines gave rise to smaller colonies, indicating a 30 
lower proliferation rate in vitro. Consistent with this, both sublines displayed a lower 31 
proliferation rate as continuously monitored in the IncuCyte live cell analysis (Fig. 4C) 32 
and reduced cell number over time as monitored in the CellTiter-Glo assay (Fig. 4D). 33 
Together with the observation that there was no consistent difference in primary 34 
tumour growth between the parental line and the sublines, these data indicate that 35 
the increased metastatic ability of the sublines is not due to the acquisition of a more 36 
proliferative phenotype.  37 
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 Next we tested whether the sublines show a difference in their migratory 1 
abilities, a characteristic linked to an increased metastatic potential. To our surprise, 2 
both sublines displayed a reduced migratory and chemotactic capacity in vitro as 3 
monitored in the IncuCyte scratch wound assay (Fig. 4E) and a Transwell 4 
chemotactic assay (Fig. 4F). These data highlight how morphology and cell 5 
behaviour in 2D adherent assays cannot be used as a predictor of metastatic 6 
behaviour in vivo. Consequently we moved to assays under non-adherent conditions. 7 
 8 
D2A1 metastatic sublines in non-adherent culture.  9 
As an example of how non-adherent assays can reveal properties of cells that are 10 
not evident in adherent assays, D2A1 parental cells and the D2A1 metastatic 11 
sublines D2A1 were seeded into tissue culture or low adherence plates and 12 
monitored for apoptosis after 24 hours (Fig. 5A). In adherent culture, essentially all 13 
cells were viable as monitored by the lack of annexin V (AV) staining and propidium 14 
iodide (PI) uptake. After 24 hours in non-adherent culture more than 50% of the 15 
D2A1 parental cells were classed as early apoptotic (AV+/PI-), late apoptotic 16 
(AV+/PI+) or necrotic (AV-/PI+), while both the D2A1-m1 and D2A1-m2 sublines 17 
showed a significantly lower level of anoikis under these conditions. To explore this 18 
further, we next plated cells into low-adherence U bottom plates (Fig. 5B). The 19 
parental cells readily assembled into dense tumour spheroids with well delineated 20 
margins, and expanded in size over time. Of the two metastatic sublines, the D2A1-21 
m1 subline again assembled into tumour spheroids but, consistently, they were less 22 
regular in shape. However, there was no difference in D2A1-m1 spheroid growth 23 
compared to the parental cells. By contrast, the D2A1-m2 subline formed less well 24 
aggregated spheroids with loosely attached cells associated with the main core. 25 
Moreover, as monitored by CellTiter-Glo, these disorganised spheroids showed a 26 
significant increase in cell number over time compared to the parental D2A1 and 27 
D2A1-m1 spheroids.   28 
 Given the less regular spheroid shape formed by the D2A1 sublines, we 29 
anticipated that the more loosely attached tumour cells might be more invasive. To 30 
address this, tumour spheroids were transferred after 3 days into a collagen matrix. 31 
At the indicated time points, collagen plugs were fixed, stained with DAPI and cell 32 
invasion into the 3D collagen matrix quantified. Surprisingly, the parental D2A1 cells 33 
were significantly more invasive than either of the metastatic sublines. Despite the 34 
limitation of using in vitro assays to model in vivo metastasis, these data point to the 35 
metastatic sublines having an enhanced metastatic capacity due to their ability to 36 
resist stress-induced anoikis.  37 
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 1 
D2A1-m2 cells promote stromal cell activation 2 
To investigate further how these differing behaviours in non-adherent culture might 3 
impact on tumour growth in vivo, primary tumours in BALB/c mice (Fig. 1B, 4 
Supplementary Figure S1A) and NSG mice (Fig. 1C) were sectioned and stained for 5 
αSMA, a marker of activated fibroblasts and endomucin, a marker of endothelial cells. 6 
The elevated levels of αSMA-positive fibroblasts and blood vessels in the D2A1-m2 7 
primary tumours in both the BALB/c immunocompetent (Fig. 6A, Supplementary 8 
Figure S1D,E) and NSG immunocompromised (Fig. 6B) mice suggest that this 9 
subline has an enhanced ability to promote stromal cell recruitment activation and 10 
this may, in part, provide a mechanistic explanation for the enhanced spontaneous 11 
dissemination of tumour cells to secondary sites.  12 
 Although stromal cell activation and recruitment observed in in vivo tumours 13 
cannot be fully recapitulated in vitro, we examined whether the metastatic sublines 14 
had an increased ability to promote directional migration of fibroblasts using the 'ibidi' 15 
µ-slide chemotaxis system. 3T3 mouse fibroblasts were plated into the central 16 
viewing chamber that is connected to two larger reservoirs on either side 17 
(Supplementary Figure S4A). By plating different cell populations into the two 18 
reservoirs, conditioned medium gradients are set up and cell migration can be 19 
monitored by time-lapse microscopy. As expected, if D2A1 cells are plated into both 20 
reservoirs, there is no bias in the directional migration of the fibroblasts (Fig. 6C; left 21 
panel). However, if D2A1 cells are plated into one reservoir and either D2A1-m1 or 22 
D2A1-m2 cells are plated into the other, the fibroblasts show preferential 23 
displacement towards the metastatic sublines over the parental cells (see 24 
Supplementary Figure S4B for individual fibroblast migration tracks). However, albeit 25 
with relatively small effects, only the D2A1-m2 subline induced a significant 26 
difference in fibroblast migration speed (velocity) and Euclidean distance migrated 27 
(Fig. 6C; middle and right panels) and a significant fibroblast chemotaxis (Rayleigh 28 
test; Supplementary Figure S4C). Finally, to assess the capacity of the metastatic 29 
sublines to promote fibroblast activation, fibroblasts were embedded into a 30 
Matrigel/collagen gel and treated with conditioned media from D2A1, D2A1-m1 or 31 
D2A1-m2 cells or with TGFβ as a positive control (Fig. 6D). Only D2A1-m2 32 
conditioned medium and TGFβ treatment resulted in a significant induction of 33 
fibroblast contractility.  Consistent with the in vivo observations (Fig. 6A) these data 34 
indicate that the D2A1-m2 subline has an enhanced ability to both recruit and 35 
activate stromal fibroblasts. 36 
 37 
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Gene expression profiling and analysis of human datasets 1 
Finally, we subjected the parental D2A1 cells and metastatic sublines to gene 2 
expression profiling. Principle component analysis revealed that each cell line was 3 
qualitatively unique, with the metastatic sublines being distinct but more closely 4 
related to each other than to the parental cells (Fig. 7A). Overall, there were 890 5 
genes differentially expressed between the D2A1-m1 cells and parental D2A1 cells, 6 
from which 323 genes were with a fold change of ≥1.5-fold. In the case of the D2A1-7 
m2 cells, 1339 genes were differentially expressed, from which 318 had a fold 8 
change ≥1.5 (Fig 7B). A comparison of the differentially expressed genes showed 9 
that approximately 50% were unique to each subline and 50% overlapped as shown 10 
in the Venn diagram (Fig 7B bottom panel). Unsupervised two-dimensional 11 
hierarchical clustering of the D2A1, D2A1-m1 and D2A1-m2 cells (based on genes 12 
with a fold change ≥1.5, using their log2 gene expression) confirmed the close 13 
relationship of the two sublines but also distinct gene expression patterns (Fig 7C). 14 
Top differentially expressed genes for D2A1-m1 vs. D2A1 and D2A1-m2 vs. D2A1 15 
are shown in Supplementary Table S1 and Supplementary Table S2, respectively. 16 
Top genes that were differentially changed in both sublines (Fig. 7B) and their 17 
average fold change are shown in Supplementary Table S3. Similarly, Ingenuity 18 
Pathway Analysis demonstrated distinct top canonical pathways, while the upstream 19 
regulators and molecular and cellular functions were highly overlapping (Fig. 7D, 20 
Supplementary Tables S4 and S5). Even though in both, D2A1-m1 and D2A1-m2 21 
cells, TGFβ1 is identified as upstream regulator, only in D2A1-m2 subline is the 22 
predictive z-score >2 fold, indicating a stronger activation of this pathway in D2A1-m2 23 
cells than in the parental and D2A1-m1 cells, and potentially accounting for the 24 
observed ability of the D2A1-m2 subline to promote stromal activation. 25 
 26 
Discussion 27 
Studying the complex mechanisms driving breast cancer metastasis and therapeutic 28 
response of advanced disease has been hampered by the lack of robust in vivo 29 
models, and in particular spontaneously metastatic syngeneic models where the 30 
interaction with an intact immune system can be studied. To date, there has been 31 
heavy reliance on the BALB/c-derived 4T1 cell line (Aslakson and Miller, 1992; 32 
Fantozzi and Christofori, 2006) as 4T1 cells, and selected 4T1 sublines, readily form 33 
primary orthotopic tumours that can spontaneously metastasise to the lungs and 34 
other secondary sites (Eckhardt et al., 2005; Fantozzi and Christofori, 2006; Yang et 35 
al., 2004). More recently Johnstone and colleagues have described the generation of 36 
a spontaneously metastatic E0771.LMB subline from the C57BL/6-derived E0771 37 
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mouse medullary mammary adenocarcinoma E0771 cell line (Johnstone et al., 2015) 1 
that provides a valuable model in a different mouse strain (Chen et al., 2017). The 2 
molecular and phenotypic characterisation of 12 mouse mammary carcinoma cell 3 
lines (Yang et al., 2017), provides valuable information for the research community 4 
but, as the authors note, the efficiency of metastatic spread with these lines lacks 5 
reproducibility, for example only 45% of the mice inoculated with parental D2A1 cells 6 
had detectable metastatic lesions in the lungs. Alternatives to syngeneic mouse cell 7 
lines are tumour prone genetically modified mice (Fantozzi and Christofori, 2006) 8 
such as those expressing a polyoma middle T (PyMT) (Guy et al., 1992a) or 9 
ErbB2/neu (Guy et al., 1992b) transgene in the mammary gland. Genetically modified 10 
models have provided powerful insights into tumour initiation and progression, but 11 
they have limitations when studying the development of distant metastases due to 12 
the variable latency and often late presentation of secondary disease, and the 13 
inability to rapidly perform additional genetic manipulation. In addition to the mouse 14 
syngeneic models, there are many human breast cancer cell lines that can be grown 15 
as xenografts in immunocompromised mice, and more recently, an increasing 16 
number of patient-derived xenografts where primary tumour material is transplanted 17 
directly into immunocompromised mice and then serially passaged. Such models 18 
have been extremely valuable in studying the heterogeneity of human disease and 19 
for monitoring response to tumour targeting agents (Bruna et al., 2016; Byrne et al., 20 
2017; Holen et al., 2017; Neve et al., 2006). However, few of these models 21 
reproducibly spontaneous metastasise. Further, the lack of a species matched 22 
stroma and the lack of an intact immune system limit the interrogation of breast 23 
cancer biology and/or the assessment of stromal targeting agents. Consequently, 24 
there remains an urgent need to develop a wider variety of syngeneic models where 25 
the different stages of the metastatic cascade can be investigated. 26 
 In this study we describe the generation and characterisation of two sublines 27 
of the poorly metastatic mouse mammary tumour cell line, D2A1. These sublines, 28 
D2A1-m1 and D2A1-m2, reproducibly give rise to spontaneous metastases from the 29 
primary tumour to the lungs, and in experimental metastasis assays readily colonise 30 
the lung, liver, and in case of the D2A1-m1 subline, bone. However, there are notable 31 
differences in the behaviour of these two sublines in vivo. In particular, the D2A1-m1 32 
subline, compared to the D2A1-m2 subline, is less efficient at disseminating from the 33 
primary tumour in a spontaneous metastasis assay but more efficient at colonising 34 
the lungs, bone and liver when inoculated via the tail vein, the left ventricle of the 35 
heart or the spleen, respectively. This would suggest that the D2A1-m1 subline has 36 
acquired properties that better enable it to extravasate from the circulation and/or 37 
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efficiently proliferate at these secondary sites and that, conversely, the D2A1-m2 has 1 
acquired properties that better enable it to disseminate from the primary tumours. 2 
 To address the potential mechanism underlying these distinct phenotypes, 3 
first we extensively characterised these cells lines in in vitro assays. In adherent 4 
cultures, the two sublines have distinct morphologies with the D2A1-m1 cells having 5 
a more elongated and the D2A1-m2 cells have a more rounded shape. However, 6 
these morphological differences did not relate to their behaviour with both sublines, 7 
surprisingly, showing a lower rate of proliferation and migration compared to the 8 
parental D2A1 cells. More revealing was their behaviour in non-adherent conditions. 9 
When normal epithelial cells are detached from a matrix, a programme of caspase-10 
mediated apoptosis, known as anoikis, is activated (Frisch and Screaton, 2001; Paoli 11 
et al., 2013). A hallmark of cancer is 'resisting cell death' (Hanahan and Weinberg, 12 
2011) and D2A1 parental cells show evidence of such resistance as evidenced by 13 
their ability to form and proliferate as free floating tumour spheroids when plated into 14 
U bottom low attachment plates. However, when plated under conditions that do not 15 
promote cell:cell contact between the detached cells (low adherent flat bottom plates) 16 
within 24 hours over 50% of the D2A1 cells show markers of apoptotic cell death, 17 
compared to <10% of the cells plated onto adherent flat bottomed plates. In the same 18 
assays, both metastatic sublines show increased resistance to anoikis, and in 19 
spheroid culture the D2A1-m2 cells show enhanced proliferative ability. 20 
Consequently, we conclude that the increased metastatic potential of the two 21 
sublines is due, at least in part, to their ability to survive in a more hostile 22 
environment. However, these in vitro studies were relatively uninformative as to why 23 
the D2A1-m1 subline shows a more aggressive behaviour in experimental metastasis 24 
assays. Some clues are provided by gene expression profiling where examination of 25 
genes differentially expressed between the D2A1-m1 subline and the parental cells 26 
revealed that upregulation of canonical pathways involved in glutathione regulation 27 
and the actin cytoskeleton, features that may provide an advantage for the cells in 28 
extravasating from the circulation and/or surviving in the foreign metastatic 29 
environments. Future studies will be required to fully address this hypothesis and it 30 
will certainly be of interest to compare the transcriptional profile of the D2A1 sublines 31 
freshly isolated from tumours, as this may well be more informative that profiling the 32 
sublines grown in culture.  33 
 More informative was the analysis of the D2A1-m2 subline. In addition to 34 
showing an increased resistance to anoikis, the D2A1-m2 primary tumours, in both 35 
immunocompetent BALB/c mice and immunocompromised NSG mice, showed 36 
striking infiltration of αSMA-positive stromal fibroblasts and pericytes. At least in part, 37 
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this phenotype could be recapitulated in vitro where we show that when presented 1 
with an option for directional migration, cultured fibroblasts preferentially migrate, at 2 
an increased velocity, towards the D2A1-m2 subline and D2A1-m2 conditioned 3 
medium, but not conditioned medium from D2A1 or D2A1-m1 cells, promoted 4 
fibroblast activation as monitored in a gel contraction assay.  A number of studies 5 
have demonstrated that an activated stroma, in particular the presence of activated 6 
pericytes on the blood vessels, is required for efficient intravasation of tumour cells 7 
from the primary tumour into the circulation (Harney et al., 2015; Viski et al., 2016; 8 
Xian et al., 2006; Yang et al., 2016) and an activated cancer-associated fibroblasts 9 
can prime tumour cells for metastatic growth (Zhang et al., 2013). The data 10 
presented here suggest that the increased efficiency of the D2A1-m2 subline to 11 
spontaneously metastasise may, at least in part, result from the ability to recruit and 12 
activate stromal cells, particularly stromal fibroblasts and pericytes. 13 
 In summary, the data presented here describes the derivation and 14 
characterisation of two new syngeneic metastatic mouse mammary carcinoma cell 15 
lines that have both overlapping and distinct behaviours when introduced into mice. 16 
Surprisingly, the ability of these cells to give rise to both spontaneous and 17 
experimental metastases in vivo, is not reflected by a more aggressive phenotype in 18 
in vitro proliferation, migration and invasion assays. However, some clues as to the 19 
mechanisms driving the metastatic phenotype have been revealed by assessing the 20 
cell lines in non-adherent culture and by examination of the tumour stroma. 21 
 22 
 23 
 24 
Methods 25 
In vivo studies 26 
All in vivo studies were performed under UK Home Office Project Licenses 70/7413 27 
and P6AB1448A granted under the Animals (Scientific Procedures) Act 1986. All 28 
studies were performed at The Institute of Cancer Research (Establishment Licence, 29 
X702B0E74 70/2902). Ethical permission was granted by the Institute of Cancer 30 
Research "Animal Welfare and Ethical Review Body" (AWERB). Female BALB/c and 31 
NSG mice (Charles River) between 6 and 12 weeks of age were housed in 32 
individually ventilated cages, monitored on a daily basis for signs of ill health and had 33 
food and water ad libitum. In all cases, experiments were terminated if the primary 34 
tumour reached a maximum allowable diameter of 15 mm or if a mouse showed 35 
signs of ill health. 36 
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 The two metastatic sublines were generated independently (see Fig. 1A). In 1 
each case, 5 x 104 D2A1 cells were injected into the 4th mammary fat pad of a single 2 
BALB/c mouse under general anaesthesia. When the primary tumour reached 12 - 3 
14 mm in diameter, lungs were dissected post-mortem, mechanically dissociated and 4 
placed into culture in DMEM (Gibco by ThermoFisher) plus 10% FBS (Gibco by 5 
ThermoFisher) and 1% penicillin/streptomycin. Medium was changed after 24 hours 6 
and then twice a week. After two weeks, when tumour cell colonies were visible, cells 7 
were replated and expanded. Once expanded, 5 x 104 cells were injected via the tail 8 
vein into a single BALB/c mouse. After 11-13 days, lungs were processed as before. 9 
The intravenous inoculation was repeated a further 2 times, each time into a single 10 
mouse. This procedure resulted in the two independently selected D2A1 sublines, 11 
D2A1-m1 and D2A1-m2.  12 
 For spontaneous metastasis assays, 5 x 104 cells were injected into the 4th 13 
mammary fat pad of BALB/c or NSG mice under general anaesthesia. Tumour 14 
growth was monitored using callipers and tumour volume calculated as 15 
0.5236 x [(width + length)/2]3 (Janik et al., 1975). Primary tumours and lung tissue 16 
were formalin-fixed and paraffin-embedded (FFPE) prior to sectioning. FFPE 17 
sections of primary tumours were stained with αSMA (Sigma, clone 1A4, 1:1000 18 
dilution) or endomucin (Santa Cruz SC-65495; 1:2000 dilution). Detection was 19 
achieved with the VectaStain ABS system and sections were scanned on the 20 
NanoZoomer Digital Pathology (Hamamatsu). HRP staining was analysed in ImageJ 21 
from ≥6 fields of view per tumour, avoiding areas of necrosis. To quantify lung tumour 22 
burden, sections taken midway through the lung and stained with haematoxylin and 23 
eosin (H&E). Sections were scanned and analysed using the NanoZoomer Digital 24 
Pathology, file names were blinded and the number of macroscopic tumour nodules 25 
(defined as having a minimum area of 1000 µm2/nodule) counted manually or 26 
quantified as % tumour burden. The % lung tumour burden was defined as (total 27 
tumour area)/(lung area) x 100 from a coronal H&E section of the lung. Where 28 
indicated, primary tumours were surgically resected under general anaesthesia. 29 
 For intravenous inoculation, 4 x 105 cells were injected into the tail vein of 30 
BALB/c mice. After 11 days mice were sacrificed. Lungs were processed as 31 
described in the spontaneous metastasis assay. For intracardiac inoculation, 2 x 105 32 
luciferase expressing cells were injected into the left ventricle of BALB/c mice under 33 
general anaesthesia. Tumour burden was analysed by ex vivo IVIS imaging. Mice 34 
were injected intraperitoneally with 150 mg/kg D-luciferin (Caliper Life Sciences) in 35 
100 µL. After 5 minutes, dissected hind limb long bones and brains were imaged 36 
using an IVIS imaging chamber (IVIS Illumina II). Luminescence measurements 37 
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(photons/second/cm2) were acquired over 1 minute and analysed using the Living 1 
Image software (PerkinElmer) by placing a constant size region of interest over the 2 
tissues. For intrasplenic inoculation, 2 x 105 luciferase expressing cells were 3 
inoculated into the spleen parenchyma of BALB/c mice under general anaesthesia. 4 
After 10 minutes, a splenectomy was performed to avoid growth of splenic tumours. 5 
Tumour burden in the liver was assessed by ex vivo IVIS imaging as described 6 
above.  7 
 8 
Cell lines 9 
D2A1 cells were from Chambers lab stocks, from stocks originally obtained from Dr. 10 
Fred Miller (Mahoney et al., 1985; Miller et al., 1989). NIH-3T3 cell were from Isacke 11 
laboratory stocks. Cells were maintained in DMEM plus 10% FBS and 1% 12 
penicillin/streptomycin. Cells were luciferase transduced with lentiviral expression 13 
particles containing a firefly luciferase gene and a blasticidin-resistance gene 14 
(Amsbio, LVP326). All cells were routinely subject to mycoplasma testing. 15 
 16 
In vitro studies 17 
For cell shape analysis, 1x103 cells/well were seeded into a ViewPlate-96 Black with 18 
optically clear bottom (PerkinElmer). After 24 hours, cells were fixed in 4% 19 
paraformaldehyde (PFA), permeabilised with 0.5% Triton X-100 prior to staining with 20 
DAPI (molecular probes, D1306, 1:10,000) and Alexa488-labeled phalloidin 21 
(molecular probes, A12379, 1:500). Automated image acquisition was performed on 22 
an Operetta high content imaging system (Perkin Elmer). Cell shapes were analysed 23 
using basic algorithms in the Harmony high content analysis software package 24 
(Perkin-Elmer). Cells were initially defined using the DAPI channel to identify the 25 
nucleus and the cytoplasm was segmented using the Alexa488 channel. After this, 26 
the Harmony software allows the extraction of cell shape parameters, including “cell 27 
roundness”. On average 1110 cells were analysed per well (n=6 wells/cell line). 28 
 For cell proliferation/viability assays, 1x103 cells/well were seeded into 96-well 29 
plates. Cell viability was quantified either by CellTiter-Glo (Promega) at the indicated 30 
time points or by time-lapse imaging and quantification of cell confluence using the 31 
Live-Cell Analysis System IncuCyte (EssenBioscience). 32 
 For colony formation assay, 50 cells/well were seeded into a 6-well plate. 33 
Tumour cell colonies were stained 7 days later with crystal violet. Plates were 34 
scanned using the GelCount (Oxford Optronix) and image analysis performed using 35 
GelCount software and ImageJ. 36 
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 For scratch wound migration assays, cells were seeded at high density to 1 
form a confluent layer in a 96 Image Lockplate (EssenBioscience). Scratches were 2 
created using a WoundMaker tool (EssenBioscience). Plates were imaged for 72 3 
hours and analysed using the Live-Cell Analysis System IncuCyte (EssenBiosience). 4 
 For the Transwell migration assay, 1x103 cells/well were seeded into 5 
IncuCyte ClearView 96-well chemotaxis plates in DMEM supplemented with 3% FBS. 6 
The bottom well contained DMEM supplemented with 10% FBS. Chemotactic 7 
migration was monitored and analysed using the IncuCyte Chemotaxis System 8 
(EssenBiosience).  9 
 For competitive fibroblast attraction assays the µ-Slide Chemotaxis system 10 
(ibidi) was used. In brief, 1.2 x 104 3T3 fibroblasts were seeded into the central 11 
observation chamber. 3 hours later, 3 x 104 D2A1 cells were seeded into the left 12 
reservoir and either D2A1, D2A1-m1 or D2A1-m2 cells into the right reservoir. 13 
Migration of 3T3 fibroblasts was imaged over 8 hours (20 minute intervals) using 14 
Slidebook 6 (3i) and a Nikon Eclipse TE2000-5 widefield microscope equipped with a 15 
plan flour 10x/0.3 ph1 wd 16 objective (Nikon) and a temperature- and CO2-16 
controlled chamber. Cell migration was analysed using the ImageJ Manual tracking 17 
and Chemotaxis and Migration Tool (ibidi) plugin. 18 
 To collect conditioned media, cells were seeded in DMEM supplemented with 19 
10% FBS and cultured until 70-80% confluency. The media was then changed to 20 
DMEM supplemented with 2% FBS. Conditioned media was collected after 24 hours 21 
and filtered prior to use. For fibroblast contraction assays, 7 x 104 3T3 fibroblasts 22 
were embedded in 100 µl of a Matrigel (final concentration 2 mg/ml, Corning) and rat 23 
tail Collagen I (final concentration 4 mg/ml, Corning) mixture and seeded onto a glass 24 
bottom dish (P24G-1.0-13-F, MatTek Corporation). After the gel was set at 37°C, 25 
conditioned medium or DMEM supplemented with 2% FBS with or without 26 
recombinant TGFβ1 (R&D Systems)(5 ng/ml) was added. After 14 days, plates were 27 
scanned and the contracted gel area was measured using ImageJ.  28 
 For apoptosis assay, 5 x 104 cells/well were plated into either a tissue culture 29 
treated or low adherence 6-well plates. 24 hours after seeding, cells were stained 30 
with the Annexin V-APC/ PI Apoptosis Detection Kit (eBioscience) and analysed 31 
using a BD Biosciences LSRII flow cytometer with FACSDIVA and FlowJo software.  32 
 For spheroid growth assays, 1 x 102 cells were seeded into ultra-low 33 
adherence 96-well round bottom plates (Corning). Spheroid growth was monitored 34 
using the Celigo Image Cytometer (Nexcelom Bioscience). Cell viability was 35 
monitored with CellTiter-Glo at the indicated time points. To ensure proper lysis of 36 
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the spheroids, the incubation time with the CellTiter-Glo reagent was extended from 1 
10 to 30 minutes before recording luminescence.  2 
For invasion assays, 2 x 104 cells were seeded into ultra-low adherence 96-3 
well round bottom plates. 3 days later, spheroids were transferred into fresh round 4 
bottom plates containing 2mg/ml collagen (rat tail collagen, Corning). After 24, 48 5 
and 72 hours collagen plugs were fixed in 4% PFA, permeabilised with 0.5% Triton 6 
X-100 and stained with DAPI. Confocal z-stacks were acquired using the 7 
ImageXpress Micro Confocal High-Content Analysis System (Molecular Devices) 8 
equipped with a 60µm pinhole spinning-disk, and a plan apo λ 10x/0.45 objective 9 
(Nikon). z-stacks were maximally projected and DAPI images were quantified using a 10 
custom-written MATLAB script. In brief, spheroids were binarised using an intensity 11 
threshold while individual cells invading into the collagen, away from the spheroid, 12 
were marked using the watershed transform, which allows separation of contacting 13 
cells. The centroid coordinates of the spheroid and individual cells were extracted 14 
and the distance d between each cell and the spheroid was calculated using 15 
Euclidean trigonometry. The mean square displacement (MSD), a global measure of 16 
invasion, was obtained using the following equation: 17 
 18 
(1) where dk is the distance (in µm) between the k cell and 19 
the spheroid and N is the total number of cells. 20 
 21 
Gene expression profiling and analysis of clinical datasets 22 
RNA from D2A1 and D2A1-m2 cultured cells (n = 3 independent biological replicates) 23 
and D2A1-m1 cultured cells (n = 2 independent biological replicates) was extracted 24 
using the RNeasy Mini kit (Qiagen). Microarray experiments were performed in two 25 
independent batches at Cambridge Genomic Services, University of Cambridge. In 26 
brief, RNA was assessed for concentration and quality using a SpectroStar (BMG 27 
Labtech) and a Bioanalyser (Agilent Technologies). The 8 RNA samples were 28 
amplified, labelled and hybridised on a MouseWG-6 v2.0 Expression BeadChip array 29 
(Illumina) following the manufacturer’s instructions. Raw expression data were 30 
extracted in R using lumi package (http://www.bioconductor.org). Data were filtered 31 
to remove any non-expressed probes (detection p > 0.01) across all samples, 32 
transformed using variance-stabilising transformation, normalised using the robust 33 
spline normalisation method, and then batch-corrected using the function (ComBat) 34 
in the R package (sva). Sample relations were estimated using principle component 35 
analysis based on 7970 genes with coefficient of variance (standard deviation/mean 36 
> 0.1). Two-sample t-tests were used to identify differentially expressed genes 37 
MSD =  1𝑁! 𝑑!!!!!!  
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between (a) D2A1 and D2A1-m1, (b) D2A1 and D2A1-m2 and (c) D2A1-m1 and 1 
D2A1-m2, using the BRB-Array Tools (https://brb.nci.gov/BRB-ArrayTools/) with a 2 
threshold of parametric p-value < 0.001. Differentially expressed genes with a fold 3 
change ≥ 1.5 were subject to Ingenuity Pathway Analysis (IPA) to identify altered 4 
pathways, where p < 0.05 were considered as significant. When multiple probes 5 
were mapped to the same gene, the most variable probe measured by interquartile 6 
range (IQR) across the samples was selected to represent the gene. Gene 7 
expression data from this study are deposited at deposited in NCBI Gene Expression 8 
Omnibus (GSE101579). 9 
 10 
Statistics 11 
Statistics were performed using GraphPad Prism 6. Unless otherwise stated, all 12 
numerical data are expressed as mean ±s.e.m. Significant outliers were identified 13 
using the Grubb’s test (α = 0.05, GraphPad Prism) and are shown as white symbols 14 
in the graphs. If not indicated otherwise, all comparisons between two groups were 15 
made using two-tailed, unpaired Student's t-test. If there was a significant difference 16 
in the variance of samples a Welch’s correction was applied. Where multiple groups 17 
over time were compared, a two-way ANOVA followed by Bonferroni post-hoc testing 18 
was performed. *, p < 0.05; ** p < 0.01; ***, p < 0.001.  19 
 20 
 21 
List of abbreviations 22 
a.u., arbitrary units 23 
AV, annexin V 24 
cps, counts per second 25 
DMEM, Dulbecco's Modified Eagle's Medium 26 
FBS, foetal bovine serum 27 
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Luc, luciferase 29 
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NSG, NOD scid gamma 31 
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 9 
Figure Legends 10 
 11 
Fig. 1 Generation of syngeneic spontaneously metastatic D2A1 sublines. A Diagram 12 
outlining the strategy for selection of the metastatic sublines (see Methods and text 13 
for details). B,C 5 x 104 D2A1, D2A1-m1 or D2A1-m2 cells were inoculated into the 14 
4th mammary fat pad of BALB/c mice (n = 5 - 6 mice per group). Growth of tumours 15 
in individual mice is shown. B Mice were culled between days 31 - 39 when the 16 
primary tumours reached a diameter of 12 - 14 mm (left panel). Metastatic burden in 17 
the lungs was monitored by % tumour area and number of lung nodules per lung 18 
section. Significant outliers are shown as white symbols. Data are mean values per 19 
mouse ±s.e.m. Shown are representative images of lung metastases (arrowheads). 20 
Scale bar, 200 µm. C Primary tumours were surgically excised when they reached ~6 21 
mm in diameter (day 13 - 15). All mice were culled on day 43 when the first mouse 22 
showed signs of ill health. Data shown are mean values per mouse ±s.e.m. for 23 
primary tumour growth and metastatic burden in the lungs as assessed by % tumour 24 
area per lung section. Significant outliers are shown as white symbols. 25 
Representative images of lung sections are shown. Scale bar, 2mm. 26 
 27 
Fig. 2 Spontaneous metastasis in an immunocompromised setting. 5 x 104 D2A1 or 28 
D2A1-m2 cells were inoculated into the 4th mammary fat pad of NOD scid gamma 29 
(NSG) mice (n = 5 mice per group). A Mean tumour volume ±s.e.m., non-significant 30 
at all time points. All mice were culled on day 28 when the first mouse showed signs 31 
of ill health. B Metastatic burden in the lung assessed as % tumour area and number 32 
of metastatic nodules per lung section. Shown are representative images. Data 33 
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shown are mean values per mouse ±s.e.m. Significant outlier is shown as white 1 
symbol. Scale bar, 2 mm.  2 
 3 
Fig. 3 Experimental metastasis assays. A 4 x 105 D2A1, D2A1-m1 or D2A1-m2 cells 4 
were inoculated via the tail vein into BALB/c mice (n = 8 mice per group). 11 days 5 
later, lungs were removed at necropsy. Data show quantification of tumour burden as 6 
monitored by % tumour area and number of lung nodules per lung section. Right 7 
panel, representative lung images. Scale bar, 2 mm. B 2 x 105 D2A1-Luc, D2A1-m1-8 
Luc or D2A1-m2-Luc cells were inoculated into the left ventricle of BALB/c mice (n = 9 
6 mice per group). 10 days later, bones and brains were removed at necropsy and 10 
IVIS imaged ex vivo. Representative ex vivo bone IVIS images are shown. Scale bar, 11 
1 cm. C 2 x 105 D2A1-Luc, D2A1-m1-Luc or D2A1-m2-Luc cells were inoculated into 12 
the spleen of BALB/c mice (n = 8 mice per group). 13 days later livers were removed 13 
at necropsy and IVIS imaged ex vivo. Shown are representative IVIS images Scale 14 
bar, 1 cm. Significant outliers are shown as white symbols. All data are mean values 15 
per mouse ±s.e.m. 16 
 17 
Fig. 4 Characterisation of the D2A1 metastatic sublines in vitro. A Upper panel, 18 
phase contrast images of D2A1, D2A1-m1 and D2A1-m2 cells. Scale bar, 200 µm. 19 
Lower panel, cells cultured on coverslips were stained with Alexa488-phalloidin and 20 
DAPI. Scale bar, 100 µm. Data shows mean values (n = 6 samples per cell line) 21 
±s.e.m. of cell roundness (see Methods). Equivalent results were obtained on 2 22 
separate occasions. B Colony formation assay. Data shows mean number of 23 
colonies and average colony area ±s.e.m., n = 3 wells per cell line. Representative 24 
images of crystal violet stained wells are shown below. Equivalent results were 25 
obtained on 3 separate occasions. C Cell proliferation monitored using the IncuCyte 26 
Live-Cell Analysis System. Data shown are mean values ±s.d., n = 6 wells per cell 27 
line. Equivalent results were obtained on 2 separate occasions. D Cell viability 28 
measured by CellTiter-Glo at the indicated time points. Data shown are mean values 29 
±s.d., n = 6 wells per cell line per time point. Equivalent results were obtained on 2 30 
separate occasions. E Wound healing assay monitored using the IncuCyte Live-Cell 31 
Analysis System. Data represents % wound closure ±s.d., n = 8 wells per cell line. 32 
Shown are representative false coloured images of cells time at 0 and at 24 hours. 33 
Scale bar, 300 µm. F Transwell chemotaxis assay. Data shown are mean values 34 
±s.e.m. (n = 3) for cells transmigrated to the lower side of the filter relative to the 35 
initial plated cells.  C-F Statistical differences were determined using 2-way ANOVA 36 
and Bonferroni post-hoc testing, with time and cell lines as independent variables. In 37 
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all cases both D2A1-m1 and D2A1-m2 are significantly different to the parental D2A1 1 
cells (P < 0.0001).  2 
 3 
Fig. 5 Characterisation of the D2A1 metastatic sublines in non-adherent culture. A 4 
D2A1, D2A1-m1 and D2A1-m2 cells were plated onto adherent tissue culture or non-5 
adherent 6-well plates and apoptosis monitored 24 hours later by annexin V/PI 6 
staining. Data shows the proportions of live (AV-/PI-), early apoptotic (AV+/PI-), late 7 
apoptotic (AV+/PI+) and necrotic (AV-/PI+) cells, mean of 3 experiments ±s.e.m., n = 8 
3 per cell line per experiment. D2A1 cells had significantly less viable cells compared 9 
to D2A1-m1 (P = 0.0114) and D2A1-m2 (P = 0.0119) cells. B Spheroid assay. Cells 10 
were plated in U bottom low adherence plates (n = 6 per cell line) and cultured for 14 11 
days. At stated time points, cell viability in the tumour spheroids was monitored by 12 
CellTiter-Glo, mean values ±s.e.m. Examples of tumour spheroid at day 14 are 13 
shown. Scale bar, 400 µm. Equivalent results were obtained on 2 separate occasions. 14 
c Invasion into a 3D collagen matrix. Spheroids were embedded into collagen and 15 
single cell invasion was monitored 24, 48 and 72 hours later by measuring the mean 16 
square displacement (MSD). Data shown are mean values ±s.e.m., n = 3 - 6 17 
spheroids per time point. Representative images at 48 hours are shown. Scale bar, 18 
400 µm. All panels, statistical differences were determined using 2-way ANOVA and 19 
Bonferroni post-hoc testing. Equivalent results were obtained on 2 separate 20 
occasions. 21 
 22 
Fig. 6 Stromal cell recruitment in primary tumours. A, B Primary tumours from the 23 
spontaneous metastasis experiments shown in Fig. 1B and Fig. 2 were sectioned 24 
and stained for the αSMA or endomucin. A BALB/c mice from Fig. 1B, B NSG mice 25 
from Fig. 2. Left panels, representative images. Scale bar, 100 µm. Right panels, 26 
quantification of staining from at least 4 tumours per group ±s.e.m. (n > 6 fields of 27 
view per tumour). Significant outlier is shown as white symbol. C Competitive 28 
fibroblast attraction assay (see Supplementary Figure S4A for experimental set up). 29 
Migration of individual 3T3 cells towards D2A1 vs. D2A1, D2A1 vs. D2A1-m1 or 30 
D2A1 vs. D2A1-m2 cells was monitored over 8 hours (n > 60 cells tracked/sample). 31 
Left panel, percentage net displacement of fibroblasts (see Supplementary Figure 32 
S4B for individual cell tracks and quantification). Middle and right panels, velocity 33 
(µm/min) and Euclidean distance (µm) of fibroblast migration. Box and whisker 34 
graphs, box extends from the 25th to 75th percentiles, middle line plotted at median, 35 
whiskers are minimum and maximum, + indicates mean of data. D Fibroblast 36 
contraction assay. Data shown are % contraction of the fibroblast containing 37 
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Matrigel/collagen gel after 14 days treatment with DMEM, TGFβ or conditioned 1 
medium from D2A1, D2A1-m1 and D2A1-m2 cells, n = 2 wells/condition. 2 
Representative images of the gels are shown. 3 
 4 
Fig. 7 Gene expression profiling. RNA was isolated from independent biological 5 
replicates (D2A1.1, .2 and .3; D2A1-m1.1 and .2; D2A1-m2.1, .2 and .3) and subject 6 
to gene expression profiling. A Principle component analysis estimating the relations 7 
of D2A1, D2A1-m1 and D2A1-m2 cells based on the genes with coefficient of 8 
variance > 0.1 across the 8 samples. B Upper panel, number of differentially 9 
expressed genes (p < 0.001, ≥ 1.5-fold change). Lower panel, number of unique and 10 
shared differentially expressed genes between D2A1-m1 and D2A1-m2 sublines. 11 
Venn diagram depicting percentages. C Dendrogram shows correlation-centred 12 
hierarchical clustering based on average linkage. Shown are tumour cell expression 13 
data of 481 genes that were significantly differentially expressed between D2A1 and 14 
D2A1-m1 or D2A1 and D2A1-m2 cells with ≥ 1.5-fold change, p < 0.001. D Top 15 
canonical pathways changed between D2A1-m1 and D2A1 as well as D2A1-m2 and 16 
D2A1 identified using IPA (p<0.05) based on the differentially expressed genes (p < 17 
0.001, ≥ 1.5-fold change). 18 
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Supplementary Figure S1 Spontaneous metastasis assay in BALB/c mice. 5 x 104 
D2A1 or D2A1-m2 cells were inoculated into the 4th mammary fat pad of BALB/c 
mice (n = 5 or 6 mice per group) and culled on day 30. A Primary tumour growth. B,C 
Spontaneous metastasis to the lung assessed by % tumour burden and number of 
metastatic nodules per lung section. Data shown are mean values per mouse +/-
SEM. D,E Primary tumours were sectioned and stained for D the activated fibroblast 
marker αSMA, or E the endothelial marker endomucin. Data shows quantification of 
staining of 6 tumours per group ±s.e.m. (n > 6 fields of view per tumour). 
  
  
 
Supplementary Figure S2 Experimental lung metastasis assay with luciferase 
tagged cells. 4 x 105 D2A1-Luc or D2A1-m2-Luc cells were inoculated intravenously 
into BALB/c mice (n = 6 mice per group). A Representative in vivo IVIS imaging on 
day 14. B Mice were culled on day 15 when the first mouse showed signs of ill health. 
Quantification of tumour burden in the lungs via ex vivo IVIS imaging. Mean values 
per mouse ±s.e.m.. Representative ex vivo lung IVIS images are shown. Scale bar, 1 
cm.  
  
  
 
Supplementary Figure S3 Phase contrast images of D2A1, D2A1-m1 and D2A1-m2 
cells grown on tissue culture plastic. Scale bar, 400 µm. 
 
 
 
  
  
Supplementary Figure S4 Competitive fibroblasts migration assay. A Diagram of 
the experimental setup for the 'ibidi' µ-slide chemotaxis system. Following the 
manufacturer's instructions, fibroblasts were injected into the central viewing 
chamber via port A. 3 hours later, D2A1 cells were injected into the left reservoir via 
port C and either D2A1, D2A1-m1 or D2A1-m2 cells were injected into the right 
reservoir via port E. Fibroblast migration in the central chamber was imaged over 8 
hours (see Methods for further details). B Paths taken by individual 3T3 fibroblasts, 
where all initial starting positions (t=0) are plotted at the origin (x=0, y=0). Red 
indicates paths with a positive net displacement towards tumour cells seeded on the 
right hand side. Black paths indicate net displacement towards the left. The 
percentage of cells exhibiting movement to the left (black) or right (red) is indicated 
and shown graphically in Fig. 6C, left panel. Coordinates of centre of mass are given 
below the panels. C Corresponding circular histograms, with p-values calculated 
using the Rayleigh test for vector data. Only D2A1-m2 cells induce a significant 
inhomogeneous distribution of fibroblast trajectories.  
 Supplementary Table S1. Top 40 genes differentially expressed in D2A1-m1 cells vs. D2A1 
cells 
Symbol Gene name Accession Number 
Fold 
change 
Parametric  
p-value 
Mgp Matrix Gla protein NM_008597 16.95 < 1e-07 
Arhgdib Rho, GDP dissociation inhibitor beta NM_007486 13.33 5.10E-05 
Fgf7 Fibroblast Growth Factor 7 NM_008008 12.35 1.71E-05 
Itgbl1 Integrin Subunit Beta Like 1 NM_145467 6.67 2.21E-05 
Thbs2 Thrombospondin 2 NM_011581 6.25 1.30E-06 
Pdgfrl Platelet-derived growth factor receptor-like NM_026840 5.88 2.70E-06 
Id4 Inhibitor of DNA binding 4 NM_031166 5.88 7.40E-06 
Tnfrsf11b TNF receptor superfamily member 11b NM_008764 5.56 2.93E-05 
Lgals7 Galectin 7 NM_008496 5.56 3.59E-05 
Akr1c18 Aldo-keto reductase family 1, member C18 NM_134066 5.00 2.40E-06 
Ly6a Lymphocyte antigen 6 complex, locus A NM_010738 5.00 4.80E-06 
Tpm2 Tropomyosin 2, beta NM_009416 5.00 1.10E-05 
Chst1 Carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 NM_023850 4.17 5.00E-07 
Ifi27 Interferon, alpha-inducible protein 27 NM_029803 4.17 8.64E-04 
AA467197  NM_001004174 4.00 3.00E-07 
Casp1 Caspase 1 NM_009807 4.00 6.88E-04 
Aqp1 Aquaporin 1 NM_007472 3.45 5.17E-05 
Krt8 Keratin 8 NM_031170 3.45 1.19E-04 
Ptrf Caveolae associated 1 NM_008986 3.23 2.70E-05 
Vcam1 Vascular cell adhesion molecule 1 NM_011693 3.23 4.65E-04 
Aqp5 Aquaporin 5 NM_009701 3.13 4.00E-07 
Ank Progressive ankylosis NM_020332 3.03 1.00E-07 
Idb4 Inhibitor of DNA binding 4 AK041164 3.03 7.50E-06 
Aldh3a1 Aldehyde dehydrogenase 3 family member A1 NM_007436 3.03 4.91E-05 
Lxn Latexin NM_016753 2.94 3.20E-06 
D14Ertd668e PHD finger protein 11D NM_199015 2.70 5.70E-06 
Tmem86a Transmembrane protein 86A NM_026436 2.70 1.77E-05 
LOC100046
616  XM_001476512 2.63 2.00E-07 
AI467606  NM_178901 2.63 1.28E-05 
Ecm1 Extracellular matrix protein 1 NM_007899 2.63 1.61E-04 
Cgn Cingulin  XM_001001375 -2.59 1.10E-06 
Tuft1 Tuftelin 1 NM_011656 -2.59 4.90E-05 
Ak3 Adenylate kinase 3 NM_021299 -2.87 1.61E-04 
Bgn Biglycan  NM_007542 -2.98 3.05E-05 
1810015A11
Rik YdjC homolog NM_026940 -3.01 5.45E-05 
Ogn Osteoglycin NM_008760 -3.10 5.62E-05 
Tpd52 Tumor protein D52 NM_009412 -3.15 5.40E-06 
Chchd10 Coiled-coil-helix-coiled-coil-helix domain containing 10 NM_175329 -3.52 4.25E-04 
4732462B05
Rik  AK028848 -4.13 1.85E-05 
Ptx3 Pentraxin related gene NM_008987 -4.85 3.93E-05 
 
 Supplementary Table S2. Top 40 genes differentially expressed in D2A1-m2 cells vs. 
D2A1 cells 
Symbol Gene name Accession number 
Fold 
change 
Parametric  
p-value 
Casp1 Caspase 1  NM_009807 10.99 4.30E-06 
Arhgdib Rho, GDP dissociation inhibitor beta NM_007486 10.99 1.22E-05 
Lgals7 Galectin 7 NM_008496 9.09 7.00E-07 
Fgf7 Fibroblast Growth Factor 7 NM_008008 7.69 6.40E-06 
Itgbl1 Integrin Subunit Beta Like 1 NM_145467 5.00 6.20E-06 
Tpm2 Tropomyosin 2, beta NM_009416 4.76 6.50E-06 
Mgp Matrix Gla protein NM_008597 4.55 5.50E-06 
Tnfrsf11b TNF receptor superfamily member 11b  NM_008764 4.17 1.45E-05 
Krt8 Keratin 8 NM_031170 3.70 5.90E-06 
Vcam1 Vascular cell adhesion molecule 1  NM_011693 3.57 4.64E-05 
Id4 Inhibitor of DNA binding 4  NM_031166 3.45 3.70E-06 
Thbs2 Thrombospondin 2 NM_011581 3.45 1.31E-05 
Pdgfrl Platelet-derived growth factor receptor-like  NM_026840 3.03 6.40E-06 
Ptrf Caveolae associated 1  NM_008986 2.86 2.80E-06 
Gadd45g Growth arrest and DNA-damage-inducible 45 gamma NM_011817 2.78 7.21E-05 
Rab32 RAB32, member RAS oncogene family NM_026405 2.70 8.90E-06 
Lxn Latexin NM_016753 2.63 9.00E-07 
Csrp2 Cysteine and glycine-rich protein 2 NM_007792 2.56 1.10E-06 
Eno3 Enolase 3 NM_007933 2.56 3.00E-06 
Sparc Secreted acidic cysteine rich glycoprotein  NM_009242 2.56 6.02E-05 
Id2 Inhibitor of DNA binding 2 NM_010496 2.56 1.15E-04 
Nuak1 NUAK family, SNF1-like kinase, 1 NM_001004363 2.50 1.40E-06 
Tmem86a transmembrane protein 86A  NM_026436 2.44 3.50E-06 
Dap death-associated protein NM_146057 2.33 4.40E-05 
AA467197  NM_001004174 2.33 6.03E-05 
Gpnmb Glycoprotein (transmembrane) nmb NM_053110 2.33 5.42E-04 
AI467606  NM_178901 2.27 1.40E-06 
Akr1c18 Aldo-keto reductase family 1, member C18 NM_134066 2.27 1.59E-04 
Csnk Casein kappa  NM_007786 -2.28 1.63E-04 
Sox12 SRY (sex determining region Y)-box 12 NM_011438 -2.32 6.10E-06 
2810003C17
Rik Allograft inflammatory factor 1-like NM_145144 -2.32 1.38E-05 
Slpi Secretory leukocyte peptidase inhibitor NM_011414 -2.36 2.79E-04 
Wfdc2 WAP four-disulfide core domain 2 NM_026323 -2.63 3.76E-05 
1810015A11
Rik YdjC homolog NM_026940 -2.69 1.23E-05 
Chchd10 Coiled-coil-helix-coiled-coil-helix domain containing 10  NM_175329 -2.74 3.09E-04 
Bgn Biglycan NM_007542 -2.83 2.00E-07 
Olfml2b Olfactomedin-like 2B  NM_177068 -2.87 7.26E-05 
LOC100048
733  XM_001481081 -3.07 1.50E-06 
Ak3 Adenylate kinase 3 NM_021299 -3.27 1.93E-05 
4732462B05
Rik  AK028848 -4.13 2.70E-06 
 
 
 Supplementary Table S3. Top 40 genes differentially expressed in both D2A1-m1 and 
D2A1-m2 vs. D2A1 cells 
Symbol Gene name Accession number 
Average fold 
change 
Arhgdib Rho, GDP dissociation inhibitor beta NM_007486 12.13 
Mgp Matrix Gla protein NM_008597 10.63 
Fgf7 Fibroblast Growth Factor 7 NM_008008 10.10 
Casp1 Caspase 1 NM_009807 7.46 
Lgals7 Galectin 7 NM_008496 7.25 
Itgbl1 Integrin Subunit Beta Like 1 NM_145467 5.88 
Tpm2 Tropomyosin 2, beta NM_009416 4.97 
Thbs2 Thrombospondin 2 NM_011581 4.93 
Tnfrsf11b TNF receptor superfamily member 11b  NM_008764 4.89 
Id4 Inhibitor of DNA binding 4  NM_031166 4.62 
Pdgfrl Platelet-derived growth factor receptor-like  NM_026840 4.54 
Akr1c18 Aldo-keto reductase family 1, member C18 NM_134066 3.58 
Krt8 Keratin 8 NM_031170 3.58 
Vcam1 Vascular cell adhesion molecule 1 NM_011693 3.40 
AA467197 	 NM_001004174 3.20 
Ptrf Caveolae associated 1 NM_008986 3.03 
Chst1 
Carbohydrate (keratan sulfate Gal-6) 
sulfotransferase 1 NM_023850 3.00 
Lxn Latexin NM_016753 2.78 
Aqp1 Aquaporin 1 NM_007472 2.76 
Idb4 Inhibitor of DNA binding 4 AK041164 2.59 
Tmem86a Transmembrane protein 86A NM_026436 2.59 
Gadd45g 
Growth arrest and DNA-damage-inducible 45 
gamma NM_011817 2.49 
Ank Progressive ankylosis NM_020332 2.45 
AI467606 	 NM_178901 2.44 
Dap death-associated protein NM_146057 2.44 
Aqp5 Aquaporin 5 NM_009701 2.38 
Axl AXL receptor tyrosine kinase NM_009465 2.27 
Ecm1 Extracellular matrix protein 1 NM_007899 2.25 
Gli2 GLI-Kruppel family member GLI2 NM_001081125 -2.31 
Tuft1 Tuftelin 1 NM_011656 -2.37 
Csnk Casein kappa  NM_007786 -2.39 
Cgn Cingulin  XM_001001375 -2.41 
Ogn Osteoglycin NM_008760 -2.67 
LOC100048733  XM_001481081 -2.81 
1810015A11Rik YdjC homolog NM_026940 -2.85 
Bgn Biglycan NM_007542 -2.91 
Ak3 Adenylate kinase 3 NM_021299 -3.07 
Chchd10 Coiled-coil-helix-coiled-coil-helix domain containing 10 NM_175329 -3.13 
Ptx3 Pentraxin related gene NM_008987 -3.46 
4732462B05Rik  AK028848 -4.13 
 
 
 Supplementary Table S4. Top cellular and molecular functions identified by IPA 
 p-value Activation 
z-score 
# genes 
D2A1-m1 vs. D2A1    
Cellular Movement 3.63E-03 - 5.69E-09  79 
 migration of cells* 5.69E-09 2.105 67 
 migration of breast cancer cell lines* 4.28E-05 2.179 14 
Cell Death and Survival 3.49E-03 - 7.79E-08  101 
 cell survival* 2.83E-03 2.012 38 
Cellular Assembly and Organisation 3.19E-03 - 6.74E-07  65 
 organization of cytoplasm* 6.74E-07 2.355 52 
 organization of cytoskeleton* 8.45E-06 2.567 46 
Cellular Function and Maintenance 3.77E-03 - 6.74E-07  103 
Cellular Development 3.50E-03 - 1.03E-06  92 
 
D2A1-m2 vs. D2A1    
Cellular Movement 2.19E-03 - 1.54E-11  82 
 cell movement* 1.54E-11 2.414 79 
 migration of cells* 4.53E-11 2.602 72 
Cell Death and Survival 1.73E-03 - 1.70E-08  105 
 cell death of connective tissue cells* 5.10E-04 2.113 21 
 cell survival* 8.36E-04 2.535 40 
 cell viability* 1.73E-03 2.604 37 
Cellular Assembly and Organisation 2.04E-03 - 4.56E-08  76 
Cellular Function and Maintenance 1.93E-03 - 4.56E-08  94 
Cellular Development 2.22E-03 - 7.64E-08  102 
 
Common in D2A1-m1 and D2A1-m2 vs. D2A1 
Cellular Movement 5.76E-03 - 7.79E-07  41 
 migration of cells* 7.49E-07 2.125 21 
Cell Morphology 5.62E-03 - 7.49E-05  21 
Cellular Assembly and Organisation 5.62E-03 - 7.49E-05  32 
Small Molecule Biochemistry 5.62E-03 - 9.36E-05  16 
Cell-To-Cell Signaling and Interaction 5.62E-03 - 1.05E-04  24 
 binding of connective tissue cells* 1.16E-03 2.394 6 
 adhesion of connective tissue cells* 4.13E-03 2.198 5 
*Predicted activation, z-score >2 or inactivation, z-score <-2 
 
  
 Supplementary Table S5. Top upstream regulators identified by IPA 
  p-value of overlap Activation z-score 
D2A1-m1 vs. D2A1    
TP53 7.17E-13 1.962 
TGFB1 2.44E-12 0.532 
HRAS 8.46E-11 1.551 
CTNNB1 1.20E-10 1.281 
ERBB2 3.15E-10 0.665 
KRAS 9.12E-10 0.561 
IKBKB 2.01E-08 1.227 
HTT* 2.25E-08 2.128 
MYC 2.28E-08 -0.576 
LH 5.19E-08 1.567 
   
D2A1-m2 vs. D2A1    
TGFB1* 8.58E-19 2.651 
TP53 2.95E-12 1.681 
MYC 6.61E-11 0.869 
TNF 3.91E-09 1.962 
TGFBR2 4.28E-09 1.083 
SMARCA4* 9.13E-09 2.159 
CTNNB1 7.10E-08 1.610 
IKBKB 8.30E-08 -0.077 
HRAS 8.39E-08 0.597 
KRAS 2.52E-07 0.077 
 
Common in D2A1-m1 and D2A1-m2 vs. D2A1 
TGFB1 1.50E-11 1.129 
KRAS 1.87E-08 0.218 
IKBKB 3.43E-08 0.705 
CTNNB1 5.50E-07 1.370 
NFKBIA 1.02E-06 -1.021 
MYC 2.58E-06 0.036 
SMO 4.62E-06   
HRAS 5.24E-06 0.186 
SMARCA4 7.66E-06 1.718 
TP53 1.06E-05 1.176 
*Predicted activation, z-score >2 or inactivation, z-score <-2 
 
